Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
This study is a FIH, open-label, multi-center, phase I/II, study which consists of a phase I dose escalation part of BLZ945 as single agent and in combination with PDR001, where two dosing regimens of BLZ945 will be evaluated. Once the MTD/RP2D for BLZ945 as a single agent is established, a phase II may commence, if signs of activity have been detected. Once the MTD/RP2D for BLZ945 in combination with PDR001 is established, a phase II part will commence.
BLZ945 will be administered orally and PDR001 will be administered i.v. every four weeks until patient experiences unacceptable toxicity, progressive disease and/or treatment is discontinued at the discretion of the Investigator or the patient.